Chief Business Officer

Chief Medical Officer

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Ascentage Pharma Begins Enrolling Patients in FDA, EMA-Cleared GLORA-4 Phase III Trial of Lisaftoclax for Blood Cancer

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

Sr. Director, Global Clinical Program Management

Ascentage Pharma is a global, clinical-stage biotechnology company focused on developing novel therapies for cancer and other diseases. The Sr. Director, Global Clinical Program Management will lead the development and optimization of integrated program strategies, ensuring cross-functional alignment and execution of development plans while managing external partnerships.

Sign up with Google

Sign in with Google